Laskawi, Raíner

[["dc.bibliographiccitation.firstpage","479"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HNO"],["dc.bibliographiccitation.lastpage","483"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2018-11-07T09:09:48Z"],["dc.date.available","2018-11-07T09:09:48Z"],["dc.date.issued","2012"],["dc.description.abstract","Involuntary facial movements are caused by various diseases. This article describes three of these diseases: blepharospasm, hemifacial spasm and facial synkinesis following facial nerve paralysis. The different etiologies, clinical symptoms and diagnosis are discussed. A common therapeutic approach for these three diseases is presented. Involuntary facial movements can be reduced or even completely suppressed by local injections of botulinum toxin."],["dc.identifier.doi","10.1007/s00106-012-2497-y"],["dc.identifier.isi","000304876600003"],["dc.identifier.pmid","22669435"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26345"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0017-6192"],["dc.title","Treatment of blepharospasm, hemifacial spasm and facial synkinesis with botulinum toxin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","452"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","HNO"],["dc.bibliographiccitation.lastpage","458"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Matthes, Philipp"],["dc.contributor.author","Kruegel, Jenny"],["dc.contributor.author","Karapantzou, Chrisanthi"],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2018-11-07T08:43:33Z"],["dc.date.available","2018-11-07T08:43:33Z"],["dc.date.issued","2010"],["dc.description.abstract","There are no regional data about the prevalence and use of botulinum toxin (BoNT) in otorhinolaryngology (ORL) departments in Germany. In order to obtain an overview of the current applications of BoNT in ORL departments a survey was carried out. Standardized multi-choice questionnaires were mailed to 150 ORL departments. In the analysis a differentiation was made between university and regional departments. Also an analysis of the whole collective of respondent hospitals was carried out. The most commonly treated indication is the Frey syndrome followed by hypersalivation due to a salivary fistula after parotidectomy, dysphagia, aesthetic application and laryngeal dystonia. The rate of return was 62% and 75% of all responding hospitals use BoNT as a therapeutic option, especially where \"off-label-use\" indications are concerned (15 out of 20 indications or 75%). BoNT is widely used as a therapeutic option with an increasing trend. Due to different applications a schedule of hospitals would be helpful in order to be able to find the nearest hospital for the appropriate indications."],["dc.identifier.doi","10.1007/s00106-009-2056-3"],["dc.identifier.isi","000277427800007"],["dc.identifier.pmid","20454883"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19998"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0017-6192"],["dc.title","Use of botulinum toxin in ORL departments in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","515"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Laryngo-Rhino-Otologie"],["dc.bibliographiccitation.lastpage","522"],["dc.bibliographiccitation.volume","92"],["dc.contributor.author","Steffen, A."],["dc.contributor.author","Beutner, D."],["dc.contributor.author","Hakim, S."],["dc.contributor.author","Jost, Wolfgang H."],["dc.contributor.author","Kahl, Kai G."],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Lencer, R."],["dc.contributor.author","Mall, V."],["dc.contributor.author","Mehrhoff, F.-W."],["dc.contributor.author","Meyners, T."],["dc.contributor.author","Schoenweiler, Rainer"],["dc.contributor.author","Schroeder, S."],["dc.contributor.author","Schroeter-Morasch, H."],["dc.contributor.author","Schuster, M."],["dc.contributor.author","Steinlechner, S."],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Zenk, Johannes"],["dc.contributor.author","Guntinas-Lichius, O."],["dc.date.accessioned","2018-11-07T09:21:28Z"],["dc.date.available","2018-11-07T09:21:28Z"],["dc.date.issued","2013"],["dc.description.abstract","Hypersalivation describes a relatively excessive salivary flow, which wets the patient himself and his surroundings. It may result because of insufficient oro-motor function, dysphagia, decreased central control and coordination. This reduces social interaction chances and burdens daily care. Multidisciplinary diagnostic and treatment evaluation is recommended already at early stage and focus on dysphagia, and saliva aspiration. Therefore, a multidisciplinary S2k guideline was developed. Diagnostic tools such as fiberoptic endoscopic evaluation of swallowing and videofluoroscopic swallowing studies generate important data on therapy selection and control. Especially traumatic and oncologic cases profit from swallowing therapy programmes in order to activate compensation mechanisms. In children with hypotonic oral muscles, oralstimulation plates can induce a relevant symptom release because of the improved lip closure. In acute hypersalivation, the pharmacologic treatment with glycopyrrolate and scopolamine in various applications is useful but its value in long-term usage critical. The injection of botulinum toxin into the salivary glands has shown safe and effective results with long lasting saliva reduction. Surgical treatment should be reserved for isolated cases. External radiation is judged as ultima ratio. Therapy effects and symptom severity has to be followed, especially in neurodegenerative cases. The resulting xerostomia should be critically evaluated by the responsible physician regarding oral and dental hygiene."],["dc.identifier.doi","10.1055/s-0033-1343414"],["dc.identifier.isi","000330526600006"],["dc.identifier.pmid","23900923"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29114"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1438-8685"],["dc.relation.issn","0935-8943"],["dc.title","Hypersalivation - Inauguration of the S2k Guideline (AWMF) in Short Form"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","665"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","HNO"],["dc.bibliographiccitation.lastpage","667"],["dc.bibliographiccitation.volume","61"],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Koehler, S."],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2018-11-07T09:22:55Z"],["dc.date.available","2018-11-07T09:22:55Z"],["dc.date.issued","2013"],["dc.description.abstract","Spastic entropion is a rare condition that predominantly affects older people. We report on a 74-year-old dementia patient who was successfully treated by botulinum toxin injections into the lower eyelid, thereby avoiding lid correction surgery. For patients with an increased risk of eyelid surgery, symptomatic therapy comprising botulinum toxin injections to the lower eyelid should be considered as an alternative treatment."],["dc.identifier.doi","10.1007/s00106-012-2626-7"],["dc.identifier.isi","000321965800018"],["dc.identifier.pmid","23247753"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29451"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0017-6192"],["dc.title","Botulinum toxin for the treatment of spastic entropion. Case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","186"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Laryngo-Rhino-Otologie"],["dc.bibliographiccitation.lastpage","192"],["dc.bibliographiccitation.volume","93"],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Niemczewska, A."],["dc.contributor.author","Schneider, S."],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Beutner, C."],["dc.contributor.author","Rohrbach, S."],["dc.date.accessioned","2018-11-07T09:43:03Z"],["dc.date.available","2018-11-07T09:43:03Z"],["dc.date.issued","2014"],["dc.description.abstract","Changes in Dose and Injection Pattern in the Botulinum Toxin Long-term Therapy of Facial Dyskinesis Background: Rare information exists about comparative long-term observations of patients with facial movement disorders. This retrospective analysis deals with the course of different parameters of injection over the time. Methods: In this study we compared the development of long-term botulinum toxin treatments of patients with blepharospasm, hemifacial spasm and synkinesis. 80 patients (n=30 blepharospasm, n=31 hemifacial spasm, n=19 synkinesis), who had at least 10 consultations for BTA-injections, were included in the retrospective analysis. The development for each entity in total dosage, increase in the number of injection points and change in dosages for each point were evaluated. Results: The over-all dosage in all 3 clinical disorders and for each single disease itself increased continuously over the time. The amount of injection points increased in the treatment of hemifacial spasm and synkinesis. The dosage per point increased most in blepharospasm between the 1. and 25. injection, but was distinctly lower in patients with hemifacial spasm and synkinesis. The increase in dosage in blepharospasm is therefore, in contrast to the other indications, mostly caused by an increase in dosage per point. In patients with hemifacial spasm and synkinesis the escalation of dosage is mainly caused by an increase of the number of injection points. Conclusion: These new aspects of the dynamic in the treatment with botulinum toxin enable the physician to understand better the dynamic of these diseases, to optimize treatment protocols."],["dc.identifier.doi","10.1055/s-0033-1358481"],["dc.identifier.isi","000332012100005"],["dc.identifier.pmid","24323508"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34094"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1438-8685"],["dc.relation.issn","0935-8943"],["dc.title","Änderung von Dosis und Injektionsmuster der Botulinumtoxin-Langzeittherapie fazialer Dyskinesien"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1065"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Clinical Oral Investigations"],["dc.bibliographiccitation.lastpage","1070"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Cordesmeyer, Robert"],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Kauffmann, Philipp"],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2018-11-07T10:13:42Z"],["dc.date.available","2018-11-07T10:13:42Z"],["dc.date.issued","2016"],["dc.description.abstract","The diagnosis and therapy of obstructive inflammatory disorders of the salivary glands have changed in the past decades following the introduction of sialoendoscopy. The aims of the present study were to analyze the relevance of sialoendoscopy using our own data and to compare the results to those of other studies. A retrospective analysis of 70 patients was performed, who were treated for obstructive disorders of the parotid and/or submandibular gland in whom sialoendoscopy was indicated. Two categories of interventions were considered: diagnostic interventional sialoendoscopy and endoscope-assisted interventions. Interventional sialoendoscopy procedures requiring extirpation of the gland were included in the analysis, as were abnormal intraductal processes that were detected during endoscopy. Treatment was successful in 58 of 67 (86.6 %) procedures (sialoendoscopy without surgical intervention n = 59; endoscope-assisted surgical intervention n = 8). Based on the underlying disease, the success rate was 88.6 % (n = 39) in patients with obstructive sialadenitis without sialolithiasis and 86.6 % (n = 19) in patients with sialolithiasis. It was not possible to draw definitive conclusions on the underlying disease from the observed pathological intraductal changes. Sialoendoscopy is an effective and safe diagnostic and therapeutic option with low complication rate. However, limiting factors such as the size or the position of potentially removable obstacles must be taken into consideration. The rate of gland extirpations can be reduced using sialoendoscopy."],["dc.identifier.doi","10.1007/s00784-015-1588-z"],["dc.identifier.isi","000376403200020"],["dc.identifier.pmid","26362777"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40487"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1436-3771"],["dc.relation.issn","1432-6981"],["dc.title","Sialoendoscopy as a diagnostic and therapeutic option for obstructive diseases of the large salivary glands-a retrospective analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1007"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","HNO"],["dc.bibliographiccitation.lastpage","1010"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Blum, Jenny"],["dc.contributor.author","Matthias, Christoph"],["dc.date.accessioned","2018-11-07T09:04:03Z"],["dc.date.available","2018-11-07T09:04:03Z"],["dc.date.issued","2012"],["dc.description.abstract","The production of sweat in the temporal skin region may be a serious problem for patients with hearing aids, active middle ear implants or cochlear implants. We report on two patients suffering from a loss of function of their hearing aid and a reduction of the \"wear comfort\" of an active middle ear implant. The patients underwent intracutaneous botulinum toxin (BTX) treatment of the temporal skin region. In both patients a distinct improvement of their complaints occurred, enabling them to use their hearing aids and active middle ear implants continuously. BTX injections are suited to improve sweat-caused complaints in patients with hearing aids, active middle ear implants and cochlear implants."],["dc.identifier.doi","10.1007/s00106-012-2530-1"],["dc.identifier.isi","000310537800010"],["dc.identifier.pmid","22733280"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25025"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0017-6192"],["dc.title","Botulinum toxin to treat sweat caused sequelae in patients with hearing aids, active middle ear implants and cochlear implants"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","959"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK"],["dc.bibliographiccitation.lastpage","963"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Kruegel, Jenny"],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Koehler, Sabrina"],["dc.contributor.author","Matthes, Philipp"],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2018-11-07T08:41:43Z"],["dc.date.available","2018-11-07T08:41:43Z"],["dc.date.issued","2010"],["dc.description.abstract","Background. A man diagnosed with Stensen's duct stenosis exhibited recurrent parotid swelling, invariably during meals. Previous parotid duct dilations and percutaneous radiotherapy were ineffective. Botulinum toxin (BTX) injections were injected into the affected gland to regulate salivary flow and reduce parotid swelling. Methods. BTX (22.5 units) was injected into the affected gland. A second treatment with 30 units BTX was carried out 7 weeks later. Two further injections followed after 4 months, respectively. The results were scored by the patient and evaluated in an examination. Results. The patient reported the disappearance of parotid swelling after 2 weeks of injections. This effect was maintained for 5 weeks after the first treatment and for 4 months after the following 2 treatments. There were no side effects. Conclusion. Here we introduce BTX as a therapeutic option for the treatment of salivary duct stenosis when other therapies are ineffective and before opting for gland extirpation. (c) 2009 Wiley Periodicals, Inc. Head Neck 32: 959-963, 2010"],["dc.identifier.doi","10.1002/hed.21150"],["dc.identifier.isi","000279530100016"],["dc.identifier.pmid","19484763"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19528"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Inc"],["dc.relation.issn","1043-3074"],["dc.title","BOTULINUM TOXIN: A NONINVASIVE OPTION FOR THE SYMPTOMATIC TREATMENT OF SALIVARY GLAND STENOSIS-A CASE REPORT"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","281"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Oral and Maxillofacial Surgery"],["dc.bibliographiccitation.lastpage","285"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Winterhoff, Jan"],["dc.contributor.author","Köhler, Sabrina"],["dc.contributor.author","Kottwitz, Laura"],["dc.contributor.author","Matthias, Christoph"],["dc.date.accessioned","2019-07-09T11:39:49Z"],["dc.date.available","2019-07-09T11:39:49Z"],["dc.date.issued","2012"],["dc.description.abstract","Salivary fistulas are a well-known sequel of parotidectomy, and successful treatment with botulinum toxin has been demonstrated in individual cases. Here, we report on 12 patients with fistulas treated following parotidectomy for various indications.Injection of botulinum toxin type A into the residual gland tissue was the initial treatment. After early intervention (within 6 weeks after development of the fistula), only one fistula remained (9 of 10 fistulas treated early only with botulinum toxin). One patient with early intervention did not want to wait for the botulinum toxin treatment to take effect and demanded early surgical revision, which was successful. In one patient with a permanent fistula, botulinum toxin treatment began 420 days after the operation and was unsuccessful. No side effects were evident after the treatment.In summary, botulinum toxin injections into the parotid tissue remaining after surgery appear to be an effective treatment for salivary fistulas following parotidectomy."],["dc.identifier.doi","10.1007/s10006-012-0375-0"],["dc.identifier.fs","593833"],["dc.identifier.pmid","23179957"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10323"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58042"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Botulinum toxin treatment of salivary fistulas following parotidectomy: follow-up results"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]